Abstract | BACKGROUND: METHODS: RESULTS: Eligible patients were randomized to one of the 2 groups with 72 per arm. We found no significant difference in the relapse rate for the 8-week treatment group compared to the 6-week group (9.7% vs 13.9%). There were no significant differences between the 6-week and 8-week groups regarding the relapse rate, period between clinical presentation and beginning of treatment, and time of relapse. Symptom resolution was achieved in all cases at a median 9.5 days and no cases experienced continuing symptoms after treatment. CONCLUSIONS: Our trial found no significant difference between 6-week and 8-week regimens of doxycycline and rifampicin plus streptomycin for the first 7 days. Further comparative studies with a large sample size should be implemented to achieve a consistent therapeutic regimen for uncomplicated brucellosis, to help identify those who may benefit from longer treatment, and to minimize adverse effects and unnecessary continuation of treatment.
|
Authors | Masoomeh Sofian, Ali-Akbar Velayati, Arezoo Aghakhani, Willi McFarland, Ali-Asghar Farazi, Mohammad Banifazl, Ali Eslamifar, Amitis Ramezani |
Journal | Scandinavian journal of infectious diseases
(Scand J Infect Dis)
Vol. 46
Issue 8
Pg. 573-7
(Aug 2014)
ISSN: 1651-1980 [Electronic] England |
PMID | 24934986
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Doxycycline
- Rifampin
- Streptomycin
|
Topics |
- Adult
- Anti-Bacterial Agents
(therapeutic use)
- Brucellosis
(drug therapy)
- Doxycycline
(therapeutic use)
- Drug Therapy, Combination
(methods)
- Female
- Humans
- Iran
- Male
- Middle Aged
- Rifampin
(therapeutic use)
- Streptomycin
(therapeutic use)
- Time Factors
- Treatment Outcome
- Young Adult
|